In The News
In The News
October 16, 2023
Oncolytic viruses: strategies, applications and challenges
HSTalks
Dr. Stephen J. Russell discusses strategies, applications and challenges with oncolytic viruses.
July 11, 2023
Modified measles helped Stacy Erholtz beat cancer. Ten years later, she returned to Rochester to celebrate
Post-Bulletin
A decade ago, Stacy Erholtz was one of two participants in a clinical trial at Mayo Clinic to see how viruses can be engineered to fight cancer.
April 11, 2023
Rochester’s Vyriad is taking its shot at cancer
Post-Bulletin
The Rochester-based Vyriad grew from Mayo Clinic’s Employee Entrepreneurship Program and has grown rapidly in the Med City.
April 3, 2023
Creating a company culture
Pulse
How Dr. Kah-Whye Peng and Dr. Stephen Russell have refocused Vyriad through culture.
December 21, 2022
Researchers generate a remodeled live-attenuated measles vaccine capable of driving nAb responses against SARS-CoV-2 spike protein
Medical Life Sciences
In a recent study researchers developed a measles virus (MeV)-vectored vaccine capable of inducing high neutralizing antibody (nAb) responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
October 18, 2022
Oncolytic virotherapy trial shows early signs in Lymphoma
Blood Cancers Today
Blood Cancers Today works with contributors to highlight recent thought-provoking and practice-changing articles in different specialties. In this edition, Nora Bennani, MD, Assistant Professor of Medicine and T-Cell Lymphoma Research Program Director at the Mayo Clinic College of Medicine and Science, highlights recent research in T-cell lymphoma.
September 19, 2022
Former Mayo Clinic administrator joins growing Rochester biotech firm as new COO
Post-Bulletin
Vyriad has added Scott Beck to its team as chief operating officer. Beck served in many roles in his 30 years at Mayo Clinic, including chief operating officer of Laboratory Services.
June 16, 2022
Beacon in Inner Space
Discovery's Edge
For Dr. Peng, holdups are not just obstacles to clear. They’re opportunities to take stock of issues that will face health care professionals and patients.
April 7, 2022
Rochester company develops COVID-19 vaccine pill
KIMT3
Interview with Dr. Kah Whye Peng discussing an oral COVID-19 vaccine developed by Vyriad.
March 18, 2022
Four Rochester women who stand out
Post-Bulletin
Mayo Clinic researcher Dr. Kah-Whye Peng, an early innovator in the field of oncolytic virotherapy, co-founded two Rochester biotech start-ups that are quickly growing into major companies.
November 12, 2021
Leveraging Virus Power To Beat Cancer With Vyriad
DNA Weekly
Vyriad is developing the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence. I sat down for a fascinating conversation with Stephen Russell, Co-founder and CEO of Vyriad, to hear about this incredible technology and its potential to transform oncology treatment forever.
October 21, 2021
Children with mild COVID-19 may not develop antibodies; oral vaccine booster shows promise in monkey study
Reuters
A COVID-19 booster vaccine that can be given by mouth to people who already have antibodies from vaccination or prior infection has yielded promising results in monkeys and is likely to be tested soon in humans, according to the company developing it. A report of the study posted on Monday on bioRxiv ahead of peer review says Vyriad is working with the U.S. Food and Drug Administration to plan human trials.
August 23, 2021
Med City firm’s test helps answer the question of how immune you are
Post-Bulletin
Immunocompromised Washington, D.C., attorney Samuel Shafner was unsure of his risks, even though he was vaccinated. A desire for more detailed answers about his immunity led him to Rochester’s Imanis Life Sciences and its Immuno-Cov test.
May 24, 2021
Using Viruses to Treat Cancer
Oncology Convention
Speaking on the latest episode of the Biotech 2050 podcast, Alice Bexon, the Chief Medical Officer for Vyriad, discussed the history of oncologic viruses and recent developments which she had been involved in
March 10, 2021
What to do it you test positive for COVID-19 today
CNET
Got a positive COVID-19 test? Take a deep breath and use this guide to make sense of the situation.
March 10, 2021
Can Non-Vaccinated People Get Vaccinated People Sick With COVID-19?
Verywell Health
Key Takeaways: Non-vaccinated people can still get vaccinated people sick with COVID-19. Vaccinated people who contract COVID-19 may have less severe symptoms because the body mounts an immune response and adapts to prevent the coronavirus from replicating. More research is needed about how the COVID-19 vaccines respond to emerging variants.
February 25, 2021
Rochester’s Vyriad developing oral COVID-19 vaccine
Post-Bulletin
Vyriad, a Rochester biotech firm founded by Mayo Clinic researchers, is developing an oral vaccine for the coronavirus that could be used as a booster in the months after the initial wave of vaccinations.
February 16, 2021
Company in Rochester, Minnesota Developing Oral COVID-19 Vaccine
FOX9
Vyriad, a scientific research lab based in Rochester, Minnesota, started working on a COVID-19 vaccine early last year and lab testing shows its delivery method and properties could give people immunity to the virus.
January 13, 2021
The 20 Hottest Digital Health Startups From Flyover Country, 2021
Observer
The Observer, in advance of the JP Morgan Healthcare Conference, names Imanis Life Sciences and sister company Vyriad as one of the hottest health startups from flyover country of 2021.
December 23, 2020
Heroes of the COVID Crisis: How Stephen Russel & Imanis Life Sciences Stepped Up to Make a Difference During the Pandemic
Authority Magazine
Imanis Life Sciences CEO and co-founder, Dr. Stephen Russell, talks to Authority Magazine about Heroes – what makes a hero, heroes in his own life, and heroes amid the current world climate.
December 17, 2020
If You’ve Already Had COVID-19, Do You Need the Vaccine? Here’s What Experts Say
Health
As the long-awaited COVID-19 vaccine distribution process begins in the United States, there’s plenty of deliberation around who gets the vaccine, and when.
December 9, 2020
New COVID-19 antibody test developed in Rochester
KAAL TV
While many wait for news of a COVID-19 vaccine in the United States, a Rochester company says it has created something that can help figure out if you can fight the virus off on your own.
December 9, 2020
Antibody test puts Rochester at forefront of tracking COVID-19 immunity
Post-Bulletin
How immune are you? That’s the question developers of a new COVID-19 antibody test or assay hope to answer for patients and doctors.
December 7, 2020
New test by Minnesota biotech firm can read COVID antibody levels
Star Tribune
So, what’s your titer? That question, still strange sounding, may soon become important as vaccines bring about the endgame for COVID-19.
November 19, 2020
Dueling quantitative COVID-19 neutralizing antibody tests roll out as vaccines approach completion
BioWorld
As COVID-19 vaccines ready themselves for market, two companies have turned their attention to what comes next – verifying whether the vaccines provide effective and lasting protection against SARS-CoV-2.
November 9, 2020
Study suggests herd immunity to COVID-19 in New York City is low
Medical News
Researchers in the United States have estimated that the proportion of people in New York City who developed antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the first wave of the coronavirus disease 2019 (COVID-19) pandemic is around one in eight.
October 4, 2020
Transforming the Treatment of Cancer with Oncolytic Viruses
Decision Resources Group "Conversations in Health"
Read moreAugust 28, 2020
Heroes of the Pandemic
Star Tribune
Six months now into this perplexing and powerful pandemic, we’ve grown accustomed to seeing our “front line” heroes whenever we venture out and also when we don’t.
July 20, 2020
Anti-cancer start-up doses first patient in new clinical trial
Post-Bulletin
Vyriad, a growing Rochester biotech firm founded by Mayo Clinic researcher Dr. Kah-Whye Peng and Dr. Stephen Russell, has started dosing of the first patient in a Phase 2 clinical trial of a possible late-stage cancer treatment.
June 11, 2020
Vyriad CEO Stephen Russell discusses neutralizing antibody testing
Myeloma Crowd Radio
Read moreMay 22, 2020
University of Minnesota’s Infectious Disease Center Urges Better Use of COVID-19 Testing
Star Tribune
Read moreMay 13, 2020
Rochester Scientists Develop First-of-its-Kind Antibody Test to Detect Protective Immunity
Med City Beat
Read moreMarch 4, 2020
Dr. Stephen Russell Participates in “Creating a Cluster of Innovation in Rochester” Podcast
Finance & Commerce
Read moreNovember 21, 2019
Rochester Cancer-Therapy Firm to Collaborate with Drugmaker on Melanoma Treatment
Star Tribune
Read moreNovember 6, 2019
Rochester Biotech Firm Strikes ‘Significant’ Deal with Drug Maker
Rochester Post-Bulletin
Read moreSeptember 3, 2019
From Concept to Company: An Anti-Cancer Idea Goes Viral
Discovery's Edge
Read moreJanuary 17, 2019
State of the Art Cancer Therapeutics Manufacturing Headquarters Celebrates Grand Opening in Rochester Next Week
Rochester Rising
Read moreJuly 27, 2018
Vyriad Expands Phase 1 Trial to Test Voyager-V1 in Combination with Bevencio for Colorectal Cancer
Immuno-Oncology News
Read moreJune 11, 2018
Mayo Clinic patient treated by massive measles dose still cancer-free 5 years later
Star Tribune
Read moreMarch 28, 2018
Mayo Clinic Biotech Spin-Off Vyriad Raising $9M for Expansion, Clinical Trials
Twin Cities Business
Read moreAugust 13, 2017
Oncolytic Virotherapy: A New Cornerstone for Immuno-Oncology
Journal of Oncology
Read more